Symbol |
BABA-SW(09988) Profit and Loss |
Yearend | 2023/03 | 2022/03 | 2021/03 | 2020/03 | 2019/03 | ||
Turnover (RMB) | 868.687B | 853.062B | 717.289B | 509.711B | 376.844B | ||
Operating profit/(loss) (RMB) | 89.185B | 59.550B | 165.578B | 166.645B | 96.221B | ||
Non-operating/Exceptional Items (RMB) | 0 | 0 | 0 | 0 | 0 | ||
Associates (RMB) | -8.063B | 14.344B | 6.984B | -5.733B | 566.000M | ||
Profit before taxation (RMB) | 81.122B | 73.894B | 172.562B | 160.912B | 96.787B | ||
Taxation (RMB) | 15.549B | 26.815B | 29.278B | 20.562B | 16.553B | ||
Minority interests (RMB) | -6.936B | -14.880B | -7.024B | -8.913B | -7.366B | ||
Net Profit (RMB) | 72.509B | 61.959B | 150.308B | 149.263B | 87.600B | ||
Depreciation (RMB) | 27.799B | 27.808B | 26.389B | 20.523B | 14.962B | ||
Interest Paid (RMB) | 5.918B | 4.909B | 4.476B | 5.180B | 5.190B | ||
Interest Capitalized (RMB) | 0 | 0 | 0 | 0 | 0 | ||
Taxation Rate (%) | 19.2 | 36.3 | 17 | 12.8 | 17.1 | ||
Turnover growth (%) | 1.8 | 18.9 | 40.7 | 35.3 | 50.6 | ||
Net Profit growth (%) | 17 | -58.8 | 0.7 | 70.4 | 36.9 | ||
Auditors' Opinion[1] | 1 | 1 | 1 | 1 |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update:5/7/2024
Powered by MegaHub Ltd Disclaimer |